Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 63 % of short-term debt in 2025; threshold 65 %.
-
Shrinking team NBB
FTE fell two years in a row, from 231.4 to 207.8.
Financials
Financial year 2025
NOVARTIS PHARMA from Machelen (Brab.), company number BE0459093476, closed financial year 2025 with a result of € 11.5 million after tax. For that financial year NOVARTIS PHARMA recorded revenue of € 378.6 million and equity of € 32.1 million. Compared with financial year 2024, the result moved from € 13.4 million to € 11.5 million. The company is profitable. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on June 5, 2026.
€ 32.1 million
▼ 32% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 11.5 million
▼ 14% vs 2024
Profit after tax over the fiscal year.
€ 67,203
Cash and bank balances on the last day of the fiscal year.
€ 26.5 million paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
207.8
▼ 2.3 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 39.1 million
▲ 4% vs 2024
€ 188,300 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 202,770
▼ 31% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 48.2 million
▼ 1% vs 2024
Loans from banks and other lenders, long and short.
€ 50 million
▲ 80% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 59 days on average.
€ 22.1 million
▲ 10% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 323,986,818 | € 340,589,236 | € 356,469,390 | € 378,550,712 | ▲ 6% |
| Profit after taxes | € -3,351,419 | € 26,062,116 | € 13,428,346 | € 11,516,937 | ▼ 14% |
| Equity | € 72,606,616 | € 33,668,732 | € 47,097,078 | € 32,114,015 | ▼ 32% |
| Total debts | € 49,509,131 | € 104,721,172 | € 97,206,080 | € 132,866,476 | ▲ 37% |
| Cash | € 149,481 | € 67,507 | € 67,436 | € 67,203 | |
| Retained profit | € -2,563,698 | € 23,498,418 | € 36,926,764 | € 21,943,701 | ▼ 41% |
| Dividend | € 0 | € 0 | € 0 | € 26,500,000 | |
| Bank debt | € 0 | € 39,902,604 | € 48,569,140 | € 48,219,921 | ▼ 1% |
| Balance sheet total | € 163,422,478 | € 161,976,769 | € 151,934,384 | € 168,763,331 | ▲ 11% |
| Employees (FTE) | 279.8 | 231.4 | 210.1 | 207.8 | ▼ 2.3 |
Key figures of NOVARTIS PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to NOVARTIS PHARMA?
What happened at NOVARTIS PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Nicolas ISTAS stepped down as director. NBB
- Andrea MAJOCCHI stepped down as director. NBB
- Federico MAMBRETTI stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 11.5 million (▼ 14% vs 2024). Source: NBB ↗
- Nicolas ISTAS became a director. NBB
- New establishment in Etterbeek. KBO
- Andrea MAJOCCHI became a director. NBB
- Federico MAMBRETTI became a director. NBB
In short
From € 3.4 million loss in 2022 to € 11.5 million profit in 2025.
Paid € 15.2 million in corporate taxes since 2022.
Best year ever: 2023, with € 26.1 million profit.
Paid out € 26.5 million in dividends to the owners in total.
Management
The shares are held by Novartis Pharma AG (98.3%) and Novartis AG (1.7%).
Directors
According to the 2025 annual accounts
since 2022 · until 2028
Andrea MAJOCCHI
Director
since 2022 · until 2028
since 2021 · until 2027
Shareholders
Novartis Pharma AG
98.3%
Novartis AG
1.7%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Kouterveldstraat 2
1831 Machelen (Brab.)
Belliardstraat 40
1040 Etterbeek
Active since 9 March 2022
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0459.093.476
- VAT number
- BE 0459.093.476
- Registered office
- Kouterveldstraat 2, 1831 Machelen (Brab.)
- Names & denominations
- NOVARTIS PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 25 October 1996
- Peppol
- Active · Active since 6 Mar 2026
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten
Overige gespecialiseerde groothandel in voedingswaren
Groothandel in andere voedingsmiddelen, neg